GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Compugen Ltd.
Compugen is an Israeli biotechnology company that uses computational methods to discover new drug targets. Its stock price is a venture bet on the success of its unique scientific platform and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Oncology immuno-therapy
Compugen Ltd. is an Israeli biotechnology company that uses computational methods to discover new drug targets in immuno-oncology. We classify it as "Immuno-oncology," where it is a technological pioneer in the search for new approaches. The graph below illustrates the dynamics of this knowledge-intensive and competitive sector.
Broad Market Index - GURU.Markets
Compugen is an Israeli biotech company that uses computational methods to discover new targets for immuno-oncology drugs. Its shares are part of the GURU.Markets index, and the chart below shows how its performance compares to the overall US market.
Change in the price of a company, segment, and market as a whole per day
CGEN - Daily change in the company's share price Compugen Ltd.
The daily fluctuations of Compugen Ltd., a company active in immuno-oncology, are a measure of the extreme volatility of the biotech sector. This metric reflects sensitivity to preclinical and clinical trial data, serving as a critical variable for assessing risk on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Compugen Ltd. is a biotech company. This chart shows the extreme volatility of the sector. Comparing it to CGEN, which uses computational methods for drug discovery, helps assess whether its innovative approach makes it more or less risky than the sector as a whole.
Daily change in the price of a broad market stock, index - GURU.Markets
Compugen uses computational technologies to discover new drug targets in immuno-oncology. It's a science-intensive biotech company whose stock moves with the pace of research. Its high volatility reflects the high risks and expectations in the fight against cancer, which impact the entire sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Compugen Ltd.
For Compugen Ltd., an Israeli biotech company, the year-over-year performance is a story about its unique computational platform for discovering new drug targets. Its market capitalization growth over the past 12 months is driven by progress in clinical trials of its immuno-oncology drugs and partnerships with giants like Bristol Myers Squibb.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compugen Ltd. is an Israeli early-stage biotech company using AI to discover new targets for cancer immunotherapy. Its stock price is highly volatile, reflecting investor confidence in its breakthrough scientific platform rather than its current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Compugen is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its immunotherapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Compugen Ltd.
Compugen uses computational methods to discover new drug targets. Its monthly growth is driven by progress in its R&D partnerships with major pharmaceutical companies. Positive news about its drug candidates moving into the next stage of clinical trials is the main driver of growth.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computer modeling to discover new targets for immuno-oncology drugs. They search for targets rather than creating the drugs themselves. The graph below shows the overall dynamics in the immunotherapy sector, where discovering new targets is key to creating the next generation of drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks using computational methods for drug discovery are bets on scientific breakthroughs. The chart below shows the overall risk appetite. Is Compugen moving in sync with the market, or are its scientific advances more important?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Compugen Ltd.
The weekly performance of Compugen, an Israeli biotech company using AI to discover new drug targets, reflects the future of pharmaceuticals. Its stock price is responding to the validation of its computer models using real clinical data and partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Compugen uses computational technologies to discover new drug targets in immuno-oncology. It's a knowledge-intensive and risky business. This chart will help you understand whether the company's weekly stock performance is driven by its own scientific breakthroughs and partnerships or reflects overall investor sentiment in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Compugen is a biotech company whose value depends on clinical trial results. Shares in this sector often move independently of the market. This chart will help you understand: do Compugen shares follow the broader market, or are news about its developments driving a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
CGEN - Market capitalization of the company Compugen Ltd.
Compugen's market capitalization chart tells the story of a biotech company using computational methods to discover new targets in immuno-oncology. Its volatile performance reflects the long and risky journey from computer modeling to clinical trials. This trajectory reflects the market's assessment of its scientific platform and partnerships with major pharmaceutical companies.
CGEN - Share of the company's market capitalization Compugen Ltd. within the market segment - Oncology immuno-therapy
Compugen is an Israeli biotech company that uses computational methods to discover new targets for cancer immunotherapy. Its market capitalization reflects the potential of its unique research platform. This chart shows how the market perceives its chances of developing breakthrough drugs.
Market capitalization of the market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computational methods to discover new targets for cancer immunotherapy. The chart below shows the market capitalization of this knowledge-intensive sector. Its dynamics reflect investors' belief that artificial intelligence can speed up and reduce the cost of drug development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Compugen is an Israeli biotech company that uses computational methods to discover new drug targets in immuno-oncology. Its market cap is a bet on its unique R&D platform. Its momentum reflects how artificial intelligence is changing the drug discovery process itself.
Book value capitalization of the company, segment and market as a whole
CGEN - Book value capitalization of the company Compugen Ltd.
Compugen's balance sheet consists of its capital and its computing platform, which uses AI to discover new targets for immuno-oncology therapies. This is the physical, digital, and scientific foundation for creating the drugs of the future. How has this biotech asset changed through partnerships with pharmaceutical giants? The chart below shows its dynamics.
CGEN - Share of the company's book capitalization Compugen Ltd. within the market segment - Oncology immuno-therapy
Compugen uses computational methods to discover new drug targets, which requires powerful computer clusters and verification labs. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovative research platform.
Market segment balance sheet capitalization - Oncology immuno-therapy
Compugen uses computational methods to discover new drug targets. It's a knowledge-intensive business, where the platform and data are its primary assets. The book value chart shows how "lightweight" the company is at the earliest stages of drug development.
Book value of all companies included in the broad market index - GURU.Markets
Compugen Ltd. uses AI to discover new targets for cancer immunotherapy. Its book value lies in its powerful computing platform and laboratories for validating predicted targets. The chart shows the material foundation that supports this "digital" approach to drug discovery.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Compugen Ltd.
Compugen doesn't search for drugs, but rather finds targets for them using AI. The chart shows the premium the market pays for its unique computing platform. This reflects its ability to accelerate R&D for the entire pharmaceutical industry, which is far more valuable than its own labs.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computational methods to discover new targets for immuno-oncology drugs. Its value lies in its unique research platform. The chart shows how much investors believe in its ability to make discoveries.
Market to book capitalization ratio for the market as a whole
Compugen Ltd. uses computational platforms to discover new targets for cancer immunotherapy. The company doesn't develop drugs itself, but rather identifies targets and then collaborates with major pharmaceutical companies. Its business is data-driven scientific discovery. This chart shows the overall valuation, but how does the market value this "search engine" for future oncology drugs?
Debts of the company, segment and market as a whole
CGEN - Company debts Compugen Ltd.
Compugen, an Israeli biotech company, uses a unique computational approach to drug discovery. This chart shows how it funds its high-tech research well before clinical trials begin. This investment is in a scientific platform that has the potential to generate numerous future drugs.
Market segment debts - Oncology immuno-therapy
Compugen Ltd. uses computational platforms to discover new drug targets in immuno-oncology. This innovative approach can accelerate development. This chart shows how the company funds its unique research model, which differs from traditional laboratory methods in biotechnology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Compugen Ltd.
Compugen is a biotech company that uses computational methods to discover new drug targets. This chart shows how dependent the company is on external funding for its cutting-edge research. Debt here represents an investment in a unique scientific platform that could lead to partnerships with pharmaceutical giants.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Compugen is a biotech company using computational methods to discover new immuno-oncology targets. This chart shows the overall debt burden in the oncology sector. It helps understand how early-stage R&D companies finance their research and how Compugen's unique model influences its financial structure.
Debt to book value of all companies in the market
Compugen Ltd. uses computational platforms to discover new drug targets. It's an early-stage biotech company whose primary assets are algorithms and scientific data. The chart of total market leverage shows how far removed the world of biotech R&D is from the traditional economy, where growth is often financed by leverage.
P/E of the company, segment and market as a whole
P/E - Compugen Ltd.
This metric for Compugen, an Israeli biopharmaceutical company, represents the valuation of its computational platform for drug discovery. The multiple reflects investors' faith in the potential of its approach for developing breakthrough immuno-oncology drugs and the value of its partnerships with major pharmaceutical companies.
P/E of the market segment - Oncology immuno-therapy
Discovering new drug targets, which Compugen uses AI to achieve, is the very beginning of pharmaceutical development. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Compugen is valued as a scientific platform, whose value depends on its ability to identify promising targets and secure partnerships with major pharmaceutical companies.
P/E of the market as a whole
Compugen Ltd. uses computational platforms to discover new drug targets in immuno-oncology. This science-intensive approach has the potential to accelerate drug development. This biotech sentiment chart helps understand how the market views this innovative R&D model and its potential for partnerships with major pharma companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Compugen Ltd.
Compugen is an Israeli biotech company using computational methods to discover new targets for immuno-oncology therapies. This chart illustrates expectations for its research platform. The trend reflects the market's assessment of the potential of its discoveries and partnerships with major pharmaceutical companies.
%20P%2FE%20Compugen%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Compugen-Ltd.&v=1772552799002 "Chart of the company's future (projected) P/E Compugen Ltd.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computational methods to discover new targets for immuno-oncology drugs. This chart shows profitability expectations for the sector. It helps understand how the market views its unique R&D platform and the potential of its discoveries, which are then licensed to major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772552799017 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Compugen Ltd. is a biotech company that uses computational methods to discover new drug targets in the field of immuno-oncology. This chart demonstrates investor appetite for innovation. For a company at the intersection of IT and biotech, it reflects the market's willingness to invest in platform-based approaches to drug development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772552799030 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Compugen Ltd.
Compugen Ltd. uses computational methods to discover new drug targets in immuno-oncology. The financial result illustrated in this chart consists of research expenses and revenue from partnerships with pharmaceutical companies that license its discoveries. It demonstrates how advanced bioinformatics can accelerate the development of next-generation drugs.
Profit of companies in the market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computational methods to discover new targets for cancer immunotherapy. Their approach enables them to identify previously unknown proteins that could form the basis for new drugs. This graph illustrates how advanced scientific platforms can create future revenue streams in the pharmaceutical industry.
Overall market profit
Compugen is an Israeli biotech company that uses computational methods to discover new targets for cancer immunotherapy. Its business model is based on partnerships with major pharmaceutical companies. For such innovators, the favorable economic environment, reflected in this chart, means greater opportunities for lucrative deals and research funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Compugen Ltd.
Compugen is a biotech company that uses computational methods to discover new targets for immuno-oncology drugs. The profit/loss forecast in this chart reflects expectations for its partnerships with large pharmaceutical companies developing the drugs it discovers.
%20profit%20of%20the%20company%20Compugen%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Compugen-Ltd.&v=1772552799093 "Graph of future (projected) profit of the company Compugen Ltd.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Compugen Ltd. uses computational platforms to discover new drug targets in the field of immuno-oncology, which it then develops internally or with partners. This graph shows the revenue forecast for the immuno-oncology sector, allowing one to assess the success of Compugen's unique, data-driven R&D model.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772552799115 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Compugen is an Israeli biotech company using computational methods to discover new drug targets in immuno-oncology. Its value depends on the success of its platform and partnerships. This chart, reflecting market sentiment, influences the willingness of investors and large pharmaceutical companies to invest in innovative R&D platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772552799136 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Compugen Ltd.
Compugen is a biotech company using computational methods to discover new targets for cancer immunotherapy. This chart shows how investors value its partnership revenue. This valuation is a bet that its unique drug discovery platform will lead to the development of new treatments.
P/S market segment - Oncology immuno-therapy
Compugen Ltd. uses computational methods and artificial intelligence to discover new drug targets in immuno-oncology. This chart shows the average market capitalization-to-revenue ratio for the biotech industry. It reflects the premium investors are willing to pay for Compugen's innovative scientific platform, which could accelerate the development of new cancer treatments.
P/S of the market as a whole
Compugen is an Israeli biotech company that uses computational methods to discover new targets for immuno-oncology drugs. This innovative approach to drug discovery is at the forefront of research and development. This market valuation chart helps understand how investors value science-intensive platform companies whose potential lies in future discoveries.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Compugen Ltd.
Compugen is a biotech company using computational methods to discover new targets for immuno-oncology drugs. This chart shows its valuation relative to future projected partnership and royalty revenues. It reflects investors' confidence in its unique drug discovery platform.
%20P%2FS%20Compugen%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Compugen-Ltd.&v=1772552799276 "The graph of the company's future (projected) P/S Compugen Ltd.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Compugen is a biotech company that uses computational methods to discover new targets for cancer immunotherapy. Their approach enables them to identify previously unknown proteins for drug development. This chart reflects how the market views their innovative scientific platform and the potential for future partnerships and revenue.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772552799332 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Compugen is a biotech company using computational methods to discover new targets for cancer immunotherapy. Its valuation is based on the potential of its discovery platform. This graph of general expectations for CGEN is a baseline. The company's success depends on the validation of its targets and partnerships, not on the overall economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772552799386 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Compugen Ltd.
This chart illustrates the financial model of a biotech company. For Compugen, it reflects revenues from upfront and milestone payments from large pharmaceutical partners (such as Bristol Myers Squibb), who license and develop its immuno-oncology drug candidates.
Sales of companies in the market segment - Oncology immuno-therapy
Compugen Ltd. uses computational methods to discover new targets for cancer immunotherapy. Its platform is the engine for drug discovery. This chart shows revenue in oncology. Compugen's discoveries could lead to the creation of a whole new class of drugs, dramatically impacting the future growth of the sector.
Overall market sales
Compugen is an Israeli biotech company that uses computational methods to discover new targets for immuno-oncology therapies. Its innovative approach has the potential to accelerate drug development. Compugen's success reflects how artificial intelligence and big data are transforming pharmaceuticals, a key economic sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Compugen Ltd.
Compugen is a biotechnology company using computational methods to discover new targets for immuno-oncology therapies. Future sales depend on the success of its partnerships with major pharmaceutical companies and its own clinical developments.
%20sales%20of%20the%20company%20Compugen%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Compugen-Ltd.&v=1772552799588 "Schedule of future (projected) sales of the company Compugen Ltd.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Compugen Ltd. uses computing platforms to discover new targets for immuno-oncology therapies. The forecast for this cutting-edge sector highlights the enormous potential for AI in medicine. The chart illustrates the enormous potential for companies that can accelerate and reduce the cost of drug development using computing.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772552799682 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Compugen is a biotech company using computational methods to discover new targets for cancer immunotherapy. Its value is based on the potential of its discoveries and partnerships with major pharmaceutical companies. This overall economic activity chart does not reflect its scientific activities but is important for assessing the overall investment climate in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772552799701 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Compugen Ltd.
Compugen Ltd. uses computational platforms to discover new drug targets in the field of immuno-oncology. Its business model is based on partnerships with major pharmaceutical companies for drug development. This chart shows the balance between the company's breakthrough research expenditures and the revenue it generates from its partnerships.
Market segment marginality - Oncology immuno-therapy
Compugen Ltd. uses computational platforms to discover new drug targets in the field of immuno-oncology. Profitability depends on successful target validation and partnerships with pharmaceutical companies. This chart illustrates the operational structure of this research-intensive business model.
Market marginality as a whole
Compugen Ltd. is an Israeli biotech company using computational methods to discover new targets for cancer immunotherapy. This chart shows average returns. In contrast, Compugen demonstrates a discovery-driven model. Its future profitability depends on the ability of its platform to identify promising targets and secure partnerships.
Employees in the company, segment and market as a whole
Number of employees in the company Compugen Ltd.
Compugen is an Israeli biotech company that uses computational methods to discover new targets for cancer immunotherapy. Its team consists primarily of scientists and bioinformatics specialists. The growth in this chart is directly related to the success of its platform in identifying promising molecules and partnerships with pharmaceutical giants.
Share of the company's employees Compugen Ltd. within the market segment - Oncology immuno-therapy
Compugen is an Israeli biotech company that uses computational methods to discover new targets for cancer immunotherapy. This chart illustrates its science-intensive approach. It shows the proportion of bioinformaticians, immunologists, and computational biologists working at the forefront of drug discovery that Compugen brings together.
Number of employees in the market segment - Oncology immuno-therapy
Compugen is a biotech company using computational methods to discover new targets for cancer immunotherapy. This graph illustrates how AI is changing pharmaceuticals. The growth of the team of bioinformaticians and scientists reflects the shift from traditional methods to data mining for breakthrough drug discovery.
Number of employees in the market as a whole
Compugen Ltd. uses computational platforms to discover new drug targets. They are a science-intensive company whose success depends on breakthroughs in research. The overall employment dynamics reflected in this graph are irrelevant to them. Their key goal is to validate their hypotheses, which will attract partners from big pharma and secure funding.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Compugen Ltd. (CGEN)
Compugen Ltd. is an Israeli biotech company that uses computational methods to discover new targets for cancer immunotherapy. This chart demonstrates their data-driven business. Their high market capitalization per employee reflects the value of their unique platform, which enables them to discover new drugs faster and more efficiently than traditional methods.
%20of%20the%20company%20Compugen%20Ltd.%20(CGEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Compugen-Ltd.-CGEN&v=1772552799978 "Chart of market capitalization per employee (in thousands of dollars) of the company Compugen Ltd. (CGEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Compugen uses computational methods to discover new drug targets. It's a unique biotech company where most of the work is done "on the computer," not "in a test tube." This graph clearly demonstrates the power of this model: a small team of scientists and programmers can create intellectual property worth hundreds of millions of dollars.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772552800028 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Compugen is a biotech company that uses computational methods to discover new targets for cancer immunotherapy. This chart shows a high employee value, as its unique R&D platform can generate numerous partnerships with major pharmaceutical companies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772552800047 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Compugen Ltd. (CGEN)
Compugen is an Israeli biotech company. They use computational platforms (AI) to discover new immuno-oncology targets and then develop drugs. This is R&D at the intersection of IT and biotech. This metric is likely negative. It shows how much the company invests in each scientist and data scientist to discover and validate new cancer treatments.
%20Chart%20Compugen%20Ltd.%20(CGEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Compugen-Ltd.-CGEN&v=1772552800075 "Company Profit Per Employee (in thousands of dollars) Chart Compugen Ltd. (CGEN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Compugen (CGEN) is a biotech company using computational platforms to discover new drug targets. This chart shows the industry average, but for CGEN, it's secondary. Their business is R&D. Their team's performance isn't measured by current profits, but by the ability of their AI platform to identify promising targets that can then be licensed to big pharma.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772552800079 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Compugen (CGEN) is a biotech company that uses computational platforms to discover new drug targets. It's an R&D company that profits from partnerships with big pharma. This chart shows how successful their team of scientists and programmers are at discovering valuable targets, and how these discoveries translate into upfront and royalty payments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772552800100 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Compugen Ltd. (CGEN)
Compugen is a biotech company that uses computational methods to discover new drug targets. This chart demonstrates the effectiveness of its R&D model. Revenue typically comes from partnerships with large pharmaceutical companies, allowing it to generate income with a small staff, which is reflected in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Compugen-Ltd.-CGEN&v=1772552800127 "Sales chart per company employee Compugen Ltd. (CGEN)")
Sales per employee in the market segment - Oncology immuno-therapy
Compugen is an Israeli biotech company using computational platforms to discover new immuno-oncology targets. Their core business is R&D and partnerships. This metric reflects how productively their research team generates revenue (through partnerships with Bristol Myers Squibb and others) by monetizing their discoveries.
Sales per employee for the market as a whole
Compugen is a biotech company using its proprietary computational platform to discover new drug targets in immuno-oncology. Their business is focused on R&D and partnerships. This chart shows revenue per employee. It reflects R&D payments from partners, not sales. This is an indicator of the effectiveness of their scientific platform: how much revenue their research staff generates.
Short shares by company, segment and market as a whole
Shares shorted by company Compugen Ltd. (CGEN)
Compugen is an Israeli biotech company using computational platforms (AI) to discover new immuno-oncology targets. This chart shows bearish bets. Bears are betting that, despite advanced AI, the company's discovered targets will prove ineffective in real-world clinical trials, which is a key risk.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Compugen-Ltd.-CGEN&v=1772552800193 "Short Shares Chart for the Company Compugen Ltd. (CGEN)")
Shares shorted by market segment - Oncology immuno-therapy
Compugen is a biotech company using computing platforms to discover new targets for cancer immunotherapy. This chart shows overall short positions in the biotech sector. A high reading reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies.
Shares shorted by the overall market
Compugen (CGEN) is a clinical-stage biotech company working in immuno-oncology. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Compugen Ltd. (CGEN)
Compugen is an Israeli biotech company developing cancer immunotherapy. The stock is highly volatile and dependent on R&D. This chart can soar above 70 on positive trial data or partnerships, signaling euphoria. Oversold territory (<30) often reflects setbacks, delays, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Compugen-Ltd.-CGEN&v=1772552800235 "RSI 14 indicator chart for the company's stock Compugen Ltd. (CGEN)")
RSI 14 Market Segment - Oncology immuno-therapy
Compugen (CGEN) is an "AI biotech." They don't *treat*, but rather *search* (using an AI platform) for *new* "targets" for immuno-oncology. The "Oncology" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is CGEN's growth a "discovery" or is *the entire* biotech "overheated?"
RSI 14 for the overall market
For Compugen, a biotech company in R&D, this chart is a lifeline. Market euphoria means open capital markets and investors' willingness to fund risky but breakthrough research. In moments of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CGEN (Compugen Ltd.)
Compugen is an Israeli biotech company using computational platforms (AI) to discover new targets in immuno-oncology. This chart shows the average 12-month forecast of analysts, representing their collective bet that their R&D platform will lead to the development of successful drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CGEN-Compugen-Ltd.&v=1772552800281 "A chart showing analyst consensus forecasts for the expected stock price. CGEN (Compugen Ltd.)")
The difference between the consensus estimate and the actual stock price CGEN (Compugen Ltd.)
Compugen (CGEN) is an Israeli biotech company that uses AI (a computing platform) to discover new targets for cancer immunotherapy. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their drug discovery platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CGEN-Compugen-Ltd.&v=1772552800282 "A chart showing the difference between the consensus forecast and the actual stock price. CGEN (Compugen Ltd.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Compugen is an Israeli biotech company that uses AI to predict and discover new targets for cancer immunotherapy. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe AI can accelerate R&D in oncology.
Analysts' consensus forecast for the overall market share price
Compugen (CGEN) is an Israeli biotech company that uses an AI platform to discover new targets for cancer immunotherapy. This chart shows the overall risk appetite. For Compugen, a high-risk discovery-stage company, overall market optimism is critical for raising capital and funding partnerships with Big Pharma.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Compugen Ltd.
Compugen (CGEN) is an Israeli next-generation biotech company. They don't blindly test molecules, but use a computational (AI) platform to predict new, previously unknown checkpoints for cancer immunotherapy. This chart is a clear indicator of faith in their R&D platform. It reflects their ability to identify new targets and forge partnerships with major pharma (like Bristol-Myers).
AKIMA Market Segment Index - Oncology immuno-therapy
Compugen is an Israeli biotech company that uses its computational AI algorithm to discover new targets for immuno-oncology drugs. This chart shows the average index for the immunotherapy sector. It helps investors assess how Compugen's AI-driven scientific approach compares to the average.
The AKIM Index for the overall market
Compugen is an Israeli biotech company using computer models to discover new cancer immunotherapy targets. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this R&D platform with partnerships (Gilead, AstraZeneca) compares to overall economic trends in biotech.
